Background: Knowledge of the role of the receptor for advanced glycation end products (RAGE), particularly its soluble form (sRAGE), and of its advanced glycation end product (AGE) ligand, N-(carboxymethyl)lysine adducts (CML), is limited in chronic heart failure (CHF) and in chronic obstructive pulmonary disease (COPD). We evaluated whether the AGE/RAGE system is activated in stable CHF and COPD, and whether plasma sRAGE and CML levels are affected by clinical and functional parameters. Materials and methods: We measured plasma levels of sRAGE and CML using a sandwich enzyme-linked immunosorbent assay (ELISA) in 143 subjects, aged ≥ 65 years, divided into five groups: 58 with CHF, 23 with COPD, 27 with CHF+COPD and 35 controls (17 healthy smokers and 18 healthy nonsmokers). Individuals with diabetes were excluded from the study. Results: Plasma levels of sRAGE and CML were higher in CHF patients than in controls [sRAGE: 0·48 (0·37-0·83) vs. 0·42 (0·29-0·52) ng/mL, P = 0·01; CML: 1·95 (1·58-2·38) vs. 1·68 (1·43-2·00) ng/mL, P = 0·01]. By contrast, sRAGE and CML were not different between both COPD and CHF+COPD patients and controls (P > 0·05). N-terminal pro-brain natriuretic peptide (Nt-pro BNP) correlated with sRAGE, but not with CML, in the patient groups: CHF (r = 0·43, P <0·001), COPD (r = 0·77, P <0·0001) and CHF/COPD (r = 0·43, P = 0·003). Conclusions: Plasma levels of sRAGE and CML are increased in CHF, but not in COPD patients. The robust association between NT-pro BNP, a diagnostic and prognostic marker in CHF, and sRAGE concentrations might suggest a possible BNP pathway of amplification of inflammation via the AGE/RAGE system.
- Advanced glycation end products
- Chronic heart failure
- Chronic obstructive pulmonary disease
- N-terminal pro-brain natriuretic peptide
- Soluble receptor for advanced glycation end products
ASJC Scopus subject areas
- Clinical Biochemistry